What Is Continuous Glucose Monitors

A continuous glucose monitor is a small wearable device that measures glucose levels in the interstitial fluid beneath the skin and transmits readings to a display or smartphone in near real time. Unlike a finger-prick glucometer that captures a single snapshot, a CGM generates a continuous data stream, producing hundreds of readings per day. This allows users to observe patterns in glucose regulation across meals, sleep, exercise, and stress.

Dysregulated blood glucose is one of the strongest predictors of accelerated aging and chronic disease. Persistently elevated glucose drives glycation of proteins, contributes to chronic low-grade inflammation, damages blood vessel linings, and promotes insulin resistance. These processes are linked to cardiovascular disease, neurodegeneration, kidney damage, and shorter healthspan. Even in individuals without a diabetes diagnosis, wide swings in glucose after meals and elevated fasting glucose can signal early metabolic dysfunction years before it appears on standard lab work.

CGMs matter for longevity because they make glucose behavior visible in a way no other tool can. A single fasting glucose or HbA1c measurement taken every few months misses the dynamic reality of how the body handles carbohydrates and stress throughout any given day. By surfacing the full glucose curve, a CGM allows users to connect specific inputs (a particular meal, a poor night of sleep, a stressful meeting) with measurable metabolic outputs. This feedback loop enables precise, individualized adjustments rather than reliance on generic dietary guidelines.

The core technology relies on an electrochemical sensor, a thin flexible filament coated with glucose oxidase enzyme. When this filament sits in the interstitial fluid just beneath the dermis, glucose in the fluid reacts with the enzyme on the filament surface, generating a small electrical current proportional to glucose concentration. A transmitter attached to the sensor converts this current into a digital reading and sends it via Bluetooth to a receiver or paired smartphone. Most devices sample every one to five minutes.

Interstitial glucose is not identical to blood glucose. Because glucose must diffuse from capillaries into interstitial fluid, CGM readings lag behind fingerstick blood measurements by roughly five to fifteen minutes. This lag is most noticeable during rapid changes, such as immediately after eating or during intense exercise. Modern CGM algorithms apply calibration models to reduce this discrepancy, and some devices use factory calibration so users never need to confirm against a fingerstick. Still, the lag matters when interpreting sharp peaks and troughs.

The data a CGM produces is typically displayed as a continuous line graph showing glucose over time. Software platforms then compute derived metrics: average glucose, glucose variability (standard deviation or coefficient of variation), time in range (the percentage of readings within a target window), and the number and magnitude of excursions above or below set thresholds. These metrics are where the clinical and practical value lies, because they translate a stream of raw numbers into patterns that can guide behavior change.

A CGM tracks glucose concentration in the interstitial fluid, sampling every one to five minutes and producing 288 or more data points per day. The raw readings are assembled into a continuous glucose trace that reveals fasting levels, post-meal excursions, overnight patterns, and the speed at which glucose rises and falls. From this trace, software calculates several derived metrics: mean glucose, estimated HbA1c, standard deviation and coefficient of variation (measures of glucose variability), time in range (the percentage of readings within a chosen target window, often 70 to 140 mg/dL), and the glucose management indicator.

Some platforms layer additional context onto the glucose data, such as food logging, activity tracking, and sleep duration, to help users identify which inputs correlate with specific glucose patterns. The result is a granular, personalized map of metabolic behavior that static blood tests cannot replicate.

Applying a CGM sensor involves cleaning a skin site (usually the back of the upper arm), pressing the applicator firmly to insert the filament, and activating the sensor through its companion app. Most sensors require a warm-up period of 30 to 60 minutes before they begin reporting data. Once active, the sensor transmits readings automatically, and no user intervention is needed unless a device requires periodic fingerstick calibration.

To extract meaningful insight, pair the glucose trace with a simple log of meals, exercise sessions, sleep times, and notable stressors. Pattern recognition improves when you test single variables: eat the same meal at different times, compare the glucose effect of a meal with and without a post-meal walk, or observe how a night of poor sleep shifts your fasting glucose the following morning. Reviewing weekly trend summaries rather than fixating on individual readings is more productive, because glucose naturally fluctuates throughout the day.

When selecting a CGM, consider sensor duration (10 to 15 days per sensor), whether the device requires fingerstick calibration or is factory-calibrated, the quality and features of the companion app, and whether it integrates with other health platforms you already use. Some CGMs require a prescription regardless of diabetes status, while others are available through direct-to-consumer metabolic health services that bundle the sensor with coaching or app-based interpretation.

Accuracy specifications matter. Look for the mean absolute relative difference (MARD) reported by the manufacturer; lower MARD values indicate closer agreement with laboratory glucose measurements. A MARD below 10 percent is considered good accuracy for current-generation devices. Adhesion quality also varies between brands and can be affected by skin type, sweat level, and activity. Third-party adhesive patches and skin barrier products can improve sensor stability for active users.

Finally, evaluate the data platform itself. Some services focus purely on displaying raw glucose data, while others provide algorithmic meal scoring, glucose predictions, or coaching recommendations. The best tool for you depends on whether you prefer to interpret your own data or want guided analysis.

The evidence base for CGMs in people with type 1 and type 2 diabetes is robust. Multiple randomized controlled trials have demonstrated that CGM use improves time in range, reduces HbA1c, and lowers the frequency of hypoglycemic episodes in diabetic populations. These devices are now standard-of-care tools endorsed by major endocrinology and diabetes organizations worldwide for insulin-dependent patients.

The evidence for CGM use in non-diabetic, metabolically healthy individuals is less developed. Observational studies have shown that even people with normal HbA1c can experience frequent glucose excursions above 140 mg/dL, and that glucose variability may be an independent risk marker for cardiovascular events and mortality. However, no large, long-term randomized trial has yet demonstrated that CGM use in healthy people leads to measurable improvements in hard health outcomes such as reduced cardiovascular events or extended lifespan. The current case for non-diabetic use rests largely on the behavioral science of biofeedback: real-time data changes behavior, and improved glucose regulation is mechanistically linked to better long-term metabolic outcomes. Whether the device itself adds durable value beyond the initial learning period remains an open question.

CGMs are generally well tolerated. The most common issues are skin irritation or allergic reaction to the adhesive, minor bleeding at the insertion site, and occasional inaccurate readings caused by sensor compression during sleep (known as compression lows). Some users develop anxiety or obsessive behavior around glucose numbers, a pattern sometimes called "glucorexia," particularly when pursuing very tight targets without clinical guidance. The sensors are not inexpensive, and costs can accumulate over months of use, especially when insurance does not cover non-diabetic applications. Interpreting CGM data without understanding normal physiological variation (such as mild post-meal rises or the dawn phenomenon) can lead to unnecessary dietary restriction or unwarranted concern.